{"id":"https://openalex.org/W2591231968","doi":"https://doi.org/10.1182/blood.v116.21.3175.3175","title":"Pharmacological Study of Antimyeloma Agents on Hemostasis","display_name":"Pharmacological Study of Antimyeloma Agents on Hemostasis","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2591231968","doi":"https://doi.org/10.1182/blood.v116.21.3175.3175","mag":"2591231968"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.3175.3175","doi":"https://doi.org/10.1182/blood.v116.21.3175.3175","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3175.3175","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000944048","display_name":"Fran\u00e7ois Mullier","orcid":"https://orcid.org/0000-0001-6947-6099","observed_orcids":["https://orcid.org/0000-0001-6947-6099"]},"institutions":[{"id":"https://openalex.org/I4210093617","display_name":"CHU Dinant Godinne UCL Namur","ror":"https://ror.org/00ntbvq76","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4210093617"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Franc\u0327ois Mullier","raw_affiliation_strings":["Hematology laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences (NARILIS), Yvoir, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences (NARILIS), Yvoir, Belgium,","institution_ids":["https://openalex.org/I4210093617","https://openalex.org/I4391767857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109245471","display_name":"S\u00e9verine Robert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149768937","display_name":"University of Namur","ror":"https://ror.org/03d1maw17","country_code":"BE","type":"education","lineage":["https://openalex.org/I149768937"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Severine Robert","raw_affiliation_strings":["Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,","institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029112107","display_name":"Philippe Devel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149768937","display_name":"University of Namur","ror":"https://ror.org/03d1maw17","country_code":"BE","type":"education","lineage":["https://openalex.org/I149768937"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Philippe Devel","raw_affiliation_strings":["Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,","institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083709033","display_name":"L\u00fctfiye Alpan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149768937","display_name":"University of Namur","ror":"https://ror.org/03d1maw17","country_code":"BE","type":"education","lineage":["https://openalex.org/I149768937"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Lutfiye Alpan","raw_affiliation_strings":["Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,","institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030493369","display_name":"Nicolas Lufin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149768937","display_name":"University of Namur","ror":"https://ror.org/03d1maw17","country_code":"BE","type":"education","lineage":["https://openalex.org/I149768937"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Nicolas Lufin","raw_affiliation_strings":["Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,","institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109892826","display_name":"Bernard Ch\u00e2telain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Bernard Chatelain","raw_affiliation_strings":["Hematology Laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences (NARILIS), Yvoir, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences (NARILIS), Yvoir, Belgium","institution_ids":["https://openalex.org/I4391767857"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041424887","display_name":"Jean\u2010Michel Dogn\u00e9","orcid":"https://orcid.org/0000-0003-2107-1804","observed_orcids":["https://orcid.org/0000-0003-2107-1804"]},"institutions":[{"id":"https://openalex.org/I149768937","display_name":"University of Namur","ror":"https://ror.org/03d1maw17","country_code":"BE","type":"education","lineage":["https://openalex.org/I149768937"]},{"id":"https://openalex.org/I4391767857","display_name":"Namur Research Institute for Life Sciences","ror":"https://ror.org/038bmak92","country_code":"BE","type":"facility","lineage":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Jean-Michel Dogne\u0301","raw_affiliation_strings":["Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, University of Namur, Namur Research Institute for LIfe Sciences (NARILIS), Namur, Belgium,","institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4391767857"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5000944048","https://openalex.org/A5029112107","https://openalex.org/A5030493369","https://openalex.org/A5041424887","https://openalex.org/A5083709033","https://openalex.org/A5109245471"],"corresponding_institution_ids":["https://openalex.org/I149768937","https://openalex.org/I4210093617","https://openalex.org/I4391767857"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"116","issue":"21","first_page":"3175","last_page":"3175"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.37869998812675476,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.37869998812675476,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.34769999980926514,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.23409999907016754,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.9290000200271606},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.7940000295639038},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/platelet-aggregation","display_name":"platelet aggregation","score":0.7979999780654907},{"id":"https://openalex.org/keywords/blood-coagulation","display_name":"coagulation","score":0.7900000214576721},{"id":"https://openalex.org/keywords/primary-hemostasis","display_name":"primary hemostasis","score":0.9129999876022339},{"id":"https://openalex.org/keywords/secondary-hemostasis","display_name":"secondary hemostasis","score":0.996999979019165},{"id":"https://openalex.org/keywords/thrombin-generation","display_name":"thrombin generation","score":0.7319999933242798},{"id":"https://openalex.org/keywords/adp-induced-platelet-aggregation","display_name":"ADP-induced aggregation","score":0.7630000114440918},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.7070000171661377},{"id":"https://openalex.org/keywords/anticoagulation-reversal","display_name":"anticoagulant reversal","score":0.46399998664855957},{"id":"https://openalex.org/keywords/argatroban","display_name":"argatroban","score":0.5659999847412109},{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.5}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8172954320907593},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.7500009536743164},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.7290908694267273},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6360650658607483},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6043938994407654},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.601834237575531},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5991363525390625},{"id":"https://openalex.org/C2778589496","wikidata":"https://www.wikidata.org/wiki/Q487937","display_name":"Hemostasis","level":2,"score":0.5562310218811035},{"id":"https://openalex.org/C2780076745","wikidata":"https://www.wikidata.org/wiki/Q613879","display_name":"Platelet-rich plasma","level":3,"score":0.5051143765449524},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.4587981104850769},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.44773122668266296},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.4115637242794037},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2951265871524811}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1182/blood.v116.21.3175.3175","doi":"https://doi.org/10.1182/blood.v116.21.3175.3175","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3175.3175","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmh:oai:pure.unamur.be:openaire_cris_publications/8cba3423-1607-4bed-a46a-2804542b755d","doi":null,"is_oa":false,"landing_page_url":"https://researchportal.unamur.be/en/publications/8cba3423-1607-4bed-a46a-2804542b755d","pdf_url":null,"source":{"id":"https://openalex.org/S4406922457","display_name":"Repository of the University of Namur","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Mullier, F, Robert, S, Devel, P, Alpan, L, Lufin, N, Chatelain, B & Dogn\u00e9, J-M 2010, Pharmacological Study of Antimyeloma Agents on Hemostasis. in BLOOD. vol. 116, pp. 1305-1305.","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7216836460","https://openalex.org/W2558681174","https://openalex.org/W6926597543","https://openalex.org/W2142846567","https://openalex.org/W1984648852","https://openalex.org/W7213947480","https://openalex.org/W2142590784","https://openalex.org/W2552229540","https://openalex.org/W2979915210","https://openalex.org/W4386785154"],"abstract_inverted_index":{"Abstract":[0,1],"3175":[2],"Introduction:":[3],"Patients":[4],"with":[5,30,39,49,123,221,277,421,431,440,444,610],"multiple":[6,611],"myeloma":[7,612],"(MM)":[8],"have":[9,62,593],"an":[10,31],"increasing":[11],"risk":[12,33,45,601],"of":[13,20,34,57,81,90,99,131,166,190,200,223,307,510,602,633],"developing":[14],"venous":[15],"thromboembolism":[16],"(VTE).":[17],"The":[18,54,88,163,599],"use":[19],"thalidomide":[21,201,441,445,549,605],"or":[22,41,69,479,531,567,606,623],"lenalidomide,":[23],"two":[24,278],"antimyeloma":[25,537,591],"agents":[26,592],"has":[27,533],"been":[28,64,534],"associated":[29,38],"increased":[32,44,600],"VTE":[35,603],"especially":[36,576],"when":[37],"dexamethasone":[40],"melphalan-prednisone.":[42],"This":[43],"in":[46,193,329,343,353,370,515,529,608],"less":[47],"pronounced":[48,439],"the":[50,78,96,153,157,167,198,207,249,271,304,316,330,344,354,361,371,403,407,448,511,520,544],"proteasome":[51],"inhibitor":[52,283,290],"bortezomib.":[53],"pharmacological":[55,97],"effects":[56,80,98,436],"thalidomide,":[58,411,574],"lenalidomide":[59,182,298,571,607],"and":[60,110,146,159,179,183,220,232,242,265,275,286,296,299,312,347,390,418,425,428,465,472,501,508,517,550,558,572,575,587],"bortezomib":[61,184,391],"never":[63],"studied":[65],"on":[66,84,102,111,202,258,266,273,318,363,395,491,526,596,621],"platelet":[67,164,204,397,412,455,492,556,562,582],"aggregation":[68,205,385,398,413,456,493,557,563,583],"coagulation.":[70],"These":[71,435],"preliminary":[72],"data":[73],"are":[74],"necessary":[75],"to":[76,94,136,140,151,156,247,570,635],"understand":[77],"differential":[79],"these":[82,100,590],"drugs":[83,101,380,538],"thrombotic":[85],"events.":[86],"Aims:":[87],"aim":[89],"our":[91],"study":[92],"is":[93,613],"investigate":[95],"primary":[103,622],"hemostasis":[104,113,625],"by":[105,173,458,565,585,604,617],"light":[106],"transmission":[107],"agregometry":[108],"(LTA)":[109],"secondary":[112,624],"using":[114],"thrombin":[115,281,512,527,597],"generation":[116],"test":[117],"(TGT).":[118],"Methods:":[119],"LTA":[120,214,377],"was":[121,138,170,211,215,255,374,414,489],"performed":[122,216,256],"a":[124,280,287,505,618],"Chrono-Log":[125],"aggregometer":[126],"(Kordia).":[127],"Platelet-rich":[128],"plasma":[129,144,263],"(PRP)":[130],"healthy":[132,168],"blood":[133],"donors":[134,169],"(n=3":[135],"10)":[137],"adjusted":[139],"300,000":[141],"platelets/\u03bcl.":[142],"Platelet-poor":[143],"(PPP)":[145],"PRP":[147,194,276,365,516,532],"were":[148,185,251,301,357,437,462,483],"used":[149,246,358,484],"respectively":[150],"adjust":[152],"photometric":[154],"measurement":[155],"minimum":[158],"maximum":[160],"optical":[161],"density.":[162],"reactivity":[165],"previously":[171],"checked":[172],"LTA.":[174],"Thalidomide":[175,293],"(racemic,":[176],"enantiomer":[177,180,470,473,578],"(+)":[178,295,442,471],"(-)),":[181,297],"spiked":[186],"at":[187,244,303,416,426,539,626],"final":[188,305,331,345,355,372],"concentration":[189,209],"200":[191,313,387,400,429,495],"\u03bcM":[192,234,327,341,351,420,423,430,433,460,467,481,496],"except":[195],"for":[196,360,409,454,468,536],"studying":[197],"influence":[199],"ADP-induced":[203],"where":[206],"maximal":[208,450],"usable":[210],"100":[212,311,419],"\u03bcM.":[213,314,388],"without":[217],"(spontaneous":[218],"aggregation)":[219],"addition":[222],"5\u03bcM":[224],"ADP,":[225],"190\u03bcg/ml":[226,477],"collagen,":[227],"600\u03bcM":[228],"arachidonic":[229],"acid":[230],"(AA)":[231],"10":[233,480],"PAR1-AP":[235,482],"(final":[236],"concentrations).":[237],"Negative":[238],"controls":[239],"(physiological":[240],"saline":[241],"DMSO":[243],"concentrations":[245,306,452,541],"dissolve":[248],"drugs)":[250],"also":[252],"included.":[253],"TGT":[254],"both":[257],"PPP":[259,320,333],"(from":[260],"normal":[261],"pool":[262],"(NPP))":[264],"PRP.":[267],"We":[268],"first":[269],"validated":[270],"method":[272],"NPP":[274,530],"anticoagulants:":[279],"direct":[282,289,619],"(i.e.":[284,291],"argatroban)":[285],"FXa":[288],"ZK-807834).":[292],"((+/\u2212),":[294],"bortezomid":[300,551],"tested":[302],"5,":[308],"10,":[309],"50,":[310],"For":[315],"experiments":[317,362],"NPP,":[319,518],"reagent":[321,334,349,366],"(5":[322],"pM":[323,337,368],"TF":[324,338,369],"+":[325,339],"4":[326,340],"PL":[328,342,352],"assays),":[332],"low":[335],"(1":[336,367],"assays)":[346,356,373],"MP":[348],"(4":[350],"whereas":[359],"PRP,":[364],"used.":[375,405,522,546],"Results:":[376],"Both":[378],"three":[379],"did":[381],"not":[382,553,560,615],"induce":[383,554],"spontaneous":[384,555],"until":[386,399,494],"Lenalidomide":[389],"showed":[392],"no":[393,487,594],"effect":[394,488,525,595],"induced":[396,457,564,584],"\u03bcM,":[401],"whatever":[402,519,543],"agonist":[404],"On":[406],"contrary,":[408],"racemic":[410],"reduced":[415],"50":[417],"5":[422],"ADP":[424,586],"150":[427],"600":[432,459],"AA.":[434,588],"more":[438],"than":[443],"(-).":[446],"So,":[447],"half":[449],"inhibitory":[451],"(IC50)":[453],"AA":[461],"127,":[463],"143":[464],"221":[466],"racemic,":[469],"(-),":[474],"respectively.":[475],"When":[476],"collagen":[478,566],"as":[485],"agonists,":[486],"observed":[490,504,535],"thalidomide.":[497],"TGT.":[498],"With":[499],"argatroban":[500],"ZK-807834,":[502],"we":[503],"concentration-dependent":[506],"decrease":[507],"delay":[509],"activity":[513,528],"profiles":[514],"inducer":[521,545],"No":[523,630],"significant":[524],"all":[540],"tested,":[542],"Conclusions:":[547],"Lenalidomide,":[548],"do":[552,559],"affect":[561],"PAR1-AP.":[568],"Conversely":[569],"bortezomib,":[573],"its":[577],"(+),":[579],"moderately":[580],"inhibits":[581],"Moreover,":[589],"generation.":[598],"patients":[609],"thus":[614],"mediated":[616],"impact":[620],"therapeutic":[627],"concentrations.":[628],"Disclosures:":[629],"relevant":[631],"conflicts":[632],"interest":[634],"declare.":[636]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-03-03T00:00:00"}